Comparison of ddI Versus Zidovudine in HIV-Infected Patients

Condition(s) targeted: HIV Infections

Intervention: Zidovudine (Drug); Didanosine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)

Official(s) and/or principal investigator(s):
R Dolin, Study Chair
M Fischl, Study Chair

To compare the effectiveness and toxicity of didanosine (ddI) and zidovudine (AZT) in patients with AIDS, advanced AIDS-related complex (ARC), or asymptomatic infection with CD4 counts < 200 cells/mm3. AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication (reproduction) of HIV with less apparent toxicity than AZT.

Official title: Comparison of 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine in Therapy of Patients With HIV Infection

Study design: Treatment

Detailed description: AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication (reproduction) of HIV with less apparent toxicity than AZT. AMENDED: 9/28/90 Patients are assigned to one of 2 treatments under a double-blind, randomly allocated, experimental design if their duration of prior AZT therapy is 0 to 16 weeks. (Patients who entered with no more than 16 weeks prior AZT and who were randomized to ddI will continue to be dosed at that level, adjusted for weight, and followed as originally planned.) Patients are assigned to one of 3 treatments as explained prior to this amendment if their duration of prior to AZT therapy is greater than 16 weeks. Original design: Patients are assigned to one of three treatments under a double-blind randomly allocated experimental design. ddI will be administered at two dose levels. It is anticipated that patients will be seen as outpatients every 2 weeks for the first 4 weeks of the study and monthly thereafter. This study continues for at least 18 months after the entry of the first subject.

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria Concurrent Medication: Required: Aerosolized pentamidine (300 mg every 4 weeks using a Respirgard II nebulizer). In the event of physiological intolerance, alternative prophylaxis may be: Trimethoprim /

sulfamethoxazole 1 DS tab per day or dapsone 50 - 100 mg/day.

Allowed: Maintenance therapy for active AIDS defining opportunistic infections for patients with 9 to 47 weeks' experience with zidovudine (AZT). Treatment of opportunistic infections with other than sulfonamide containing drugs: Pyrimethamine and sulfadiazine or clindamycin for suppression of toxoplasmosis acquired after study entry; fluconazole or amphotericin B for suppression of cryptococcosis or ketoconazole for candidiasis. Intravenous acyclovir for up to 10 days. Erythropoietin for patients under the relevant treatment IND. Analgesics, antihistamines, antiemetics, antidiarrheal agents for symptomatic therapy for toxicities. Isoniazid (INH) if no other acceptable therapy is available. Metronidazole may be used for single courses of therapy not to exceed 14 days within consecutive 90 day intervals. Note: Ketoconazole and dapsone should be taken 2 hours before or 2 hours after taking ddI (amendment 5/20/91). Concurrent Treatment: Allowed: Blood transfusions for hemoglobin toxicity. Patients must: Have a diagnosis of AIDS or advanced AIDS related complex (ARC), or per 8/09/90 amendment, asymptomatic HIV infection with CD4 count = or < 200 cells/mm3. Be either naive to zidovudine (AZT) or have taken AZT for = or < 48 weeks. Have ended treatment for acute Pneumocystis carinii pneumonia (PCP) at least 2 weeks before study entry. For patients with 2 months or less experience with AZT, PCP infection will be the single and only AIDS-defining infection and must have been within 120 days of study entry. Per amendment, other AIDS-defining conditions are allowed in the 8 weeks prior to study entry (for patients in the AZT stratum).Only one episode of PCP is permitted unless patient has > 2 months AZT experience in which case > 1 prior episode of PCP infection is allowed. Not have experienced a major intolerance to AZT at doses of at least 500 mg if the patient was on AZT therapy for = or < 48 weeks. A major intolerance is defined as recurrent grade 3 or greater toxicity which results in discontinuation of drug. Allowed: Basal cell carcinoma. In situ carcinoma of the cervix. Occasional premature atrial or ventricular contraction. Patients developing new opportunistic infections after study entry will remain on this protocol. Patients whose AIDS-defining condition is Kaposi's sarcoma alone must have CD4 cell counts < 300 cells/mm3. Prior Medication: Allowed: Previous treatment with zidovudine (AZT) up to 48 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or diseases are excluded: Kaposi's sarcoma (KS) with evidence of visceral disease or where KS requires chemotherapy; subjects with localized KS having CD4 counts = or > 200 cells/mm3. AIDS-dementia complex = or > stage 2. Prior history of acute pancreatitis within past 2 years or chronic pancreatitis. Intractable diarrhea. History of seizures within past 6 months or currently requiring anticonvulsants for control. History of past or current heart disease. Presence of a malignancy likely in the investigators opinion to require cytotoxic myelosuppressive chemotherapy during the expected course of this trial. Concurrent Medication: Excluded: Oral acidifying agents. Neurotoxic drugs. NOTE: If patients require therapy for PCP with IV pentamidine, study mediation is stopped. Patients with the following are excluded: Active AIDS defining events. Maintenance therapy for prior AIDS-defining opportunistic infections is permitted. Intolerance to AZT at doses of 500 mg because of recurrent grade 3 toxicity or greater which resulted in discontinuation of drug. Neoplasms not specifically allowed. Previous enrollment in any study of ddI, ddC or d4T. > 48 weeks of AZT therapy. An opportunistic infection not adequately controlled with suppressive therapies allowed in the protocol. Psychological or emotional problems sufficient, in the investigator's opinion, to prevent adequate compliance study therapy. Life expectancy = or < 6 months. Prior Medication: Excluded: Ganciclovir. AZT for = or > 48 weeks. Excluded within 14 days of study entry: Erythropoietin (Eprex). Excluded within 30 days of study entry: Anti-HIV therapy other than AZT. Biologic response modifiers. Other investigational drugs. Corticosteroids. Neurotoxic drugs. Excluded within 90 days of study entry: Ribavirin. Prior Treatment: Excluded within 14 days of study entry: Transfusion. Active alcohol or drug abuse sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.

San Juan Veterans Administration Med Ctr, San Juan 009275800, Puerto Rico

Univ of California / San Diego Treatment Ctr, San Diego, California 921036325, United States

Sepulveda Veterans Adm Med Ctr / Olive View Med Ctr, Sylmar, California 91342, United States

Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto, California 94304, United States

Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California 900276016, United States

Los Angeles County - USC Med Ctr, Los Angeles, California 90033, United States

Stanford Univ School of Medicine, Stanford, California 94305, United States

Harbor UCLA Med Ctr, Torrance, California 90502, United States

Olive View Med Ctr, Sylmar, California 91342, United States

Univ of Colorado Health Sciences Ctr, Denver, Colorado 80262, United States

Mountain States Regional Hemophilia Ctr / Univ of Colorado, Denver, Colorado 80262, United States

Whitman - Walker Clinic, Washington, District of Columbia 20009, United States

George Washington Univ Med Ctr, Washington, District of Columbia 20037, United States

Univ of Miami School of Medicine, Miami, Florida 331361013, United States

G E Morey Jr, Fort Lauderdale, Florida 33316, United States

Cook County Hosp, Chicago, Illinois 60612, United States

Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois 60612, United States

Edward Hines Veterans Administration Hosp, Hines, Illinois 60141, United States

Northwestern Univ Med School, Chicago, Illinois 60611, United States

Indiana Univ Hosp, Indianapolis, Indiana 462025250, United States

Univ of Kansas School of Medicine, Wichita, Kansas 67214, United States

Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana 70112, United States

Louisiana State Univ Med Ctr / Tulane Med School, New Orleans, Louisiana 70112, United States

Tulane Univ School of Medicine, New Orleans, Louisiana 70112, United States

Louisiana Comprehensive Hemophilia Care Ctr, New Orleans, Louisiana 70112, United States

Johns Hopkins Hosp, Baltimore, Maryland 21287, United States

Harvard (Massachusetts Gen Hosp), Boston, Massachusetts 02114, United States

Beth Israel Deaconess Med Ctr, Boston, Massachusetts 02215, United States

Beth Israel Deaconess - West Campus, Boston, Massachusetts 02215, United States

Boston Med Ctr, Boston, Massachusetts 02118, United States

Baystate Med Ctr of Springfield, Springfield, Massachusetts 01199, United States

Univ of Massachusetts Med Ctr, Worcester, Massachusetts 01655, United States

Med Ctr of Central Massachusetts, Worcester, Massachusetts 01605, United States

Univ of Minnesota, Minneapolis, Minnesota 55455, United States

Nebraska Regional Hemophilia Ctr, Omaha, Nebraska 68105, United States

SUNY / State Univ of New York, Syracuse, New York 13210, United States

SUNY - Stony Brook, Stony Brook, New York 117948153, United States

Univ of Rochester Medical Center, Rochester, New York 14642, United States

Bellevue Hosp / New York Univ Med Ctr, New York, New York 10016, United States

Mount Sinai Med Ctr, New York, New York 10029, United States

Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York 10465, United States

Cornell Univ Med Ctr, New York, New York 10021, United States

Saint Luke's - Roosevelt Hosp Ctr, New York, New York 10025, United States

Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York 10461, United States

Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York 10467, United States

Bronx Veterans Administration / Mount Sinai Hosp, Bronx, New York 10468, United States

SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York 14215, United States

Mem Sloan - Kettering Cancer Ctr, New York, New York 10021, United States

Beth Israel Med Ctr / Peter Krueger Clinic, New York, New York 10003, United States

City Hosp Ctr at Elmhurst / Mount Sinai Hosp, Elmhurst, New York 11373, United States

Univ of North Carolina, Chapel Hill, North Carolina 275997215, United States

Duke Univ Med Ctr, Durham, North Carolina 27710, United States

Bowman Gray School of Medicine / Wake Forest Univ, Winston Salem, North Carolina 27103, United States

Ohio State Univ Hosp Clinic, Columbus, Ohio 432101228, United States

Med College of Ohio, Toledo, Ohio 43699, United States

Holmes Hosp / Univ of Cincinnati Med Ctr, Cincinnati, Ohio 452670405, United States

Milton S Hershey Med Ctr, Hershey, Pennsylvania 170330850, United States

Hemophilia Ctr of Western PA / Univ of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States

Univ of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States

Julio Arroyo, West Columbia, South Carolina 29169, United States

Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr, Knoxville, Tennessee 37920, United States

Univ TX Galveston Med Branch, Galveston, Texas 77550, United States

Hermann Hosp / Univ Texas Health Science Ctr, Houston, Texas 77030, United States

Texas Children's Hosp / Baylor Univ, Houston, Texas 77030, United States

Univ of Utah School of Medicine, Salt Lake City, Utah 84132, United States

Dr Stephen L Green, Hampton, Virginia 23666, United States

Univ of Washington, Seattle, Washington 98105, United States

Great Lakes Hemophilia Foundation, Milwaukee, Wisconsin 53233, United States

Dr Brian Buggy, Milwaukee, Wisconsin 53215, United States

Milwaukee County Med Complex, Milwaukee, Wisconsin 53226, United States

Click here for more information about zidovudine

Click here for more information about didanosine

Related publications:

Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Arch Intern Med. 1995 May 8;155(9):961-74.

Bozzette SA, Hays RD, Berry SH, Kanouse DE. A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity. Med Care. 1994 Jul;32(7):716-31.

Fiscus SA, Heggem-Snow A, Troiani L, Wallmark E, Folds JD, Sheff B, van der Horst CM. Transient high titers of HIV-1 in plasma and progression of disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 May 1;9(1):51-7.

Schooley RT. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS. 1995 Dec;9 Suppl 2:S15-S19. Review.

Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med. 1994 Aug 15;121(4):263-8.

Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):169-74.

Spino C, Kahn JO, Dolin R, Phair JP. Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):346-55.

Last updated: June 23, 2005